The industry looks set to continue a preference for European outsourcing facilities as national tax systems exert influence.

Our editorial team delve into the key takeaways from the 2026 HLTH Europe conference and the 2026 BIO International Convention.

Ipsen’s Memo acquisition is the second the former has signed this week alone, following its blockbuster Kartos buyout on 29 June.

Bocunebart's PACAP-targeting mechanism positions it as a potential first-in-class therapy in a thin pipeline of novel late-stage candidates ...

Inocras has entered a strategic partnership with AimedBio to enhance cancer drug development using whole genome intelligence.

In Sanofi's Baby-COMET trial, Nexviazyme met all primary and secondary endpoints, teeing it up for potential label expansion in Pompe disease.

The retraction further weakens Amgen’s case for Tavneos’ continued use on the market as the drug comes under intense regulatory scrutiny.

The US FDA has declined to approve Unicycive Therapeutics’ resubmitted NDA for OLC to treat hyperphosphatemia in CKD patients on dialysis.

Eli Lilly and Company has entered into an agreement with Innovent Biologics for the commercialisation of Verzenios in mainland China.

Less than a year after emerging from stealth, Danish-based QuantumCell has signed a multi-billion-dollar deal to equip its pipeline with Alzheimer’s drug technology. The biotech has entered into a ...

AbbVie presented new results from the Phase III ECLIPSE trial (NCT06241313) at this year's Congress of the European Academy of Neurology (EAN).

The number of RMAT designations awarded by the FDA increased sharply from 2024, reaching a record of 48 RMAT designations in 2025.